Biotest AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Biotest AG - overview
Established
1946
Location
Dreieich, -, Germany
Primary Industry
Pharmaceuticals
About
Biotest AG is a specialized biopharmaceutical company focused on developing, producing, and marketing innovative medical therapies for hematology and clinical immunology. Their products aim to improve patient outcomes in critical healthcare areas. Founded in 1946 and headquartered in Dreieich, Germany, Biotest AG develops therapies for hematology and immunology. The company underwent a significant change when, in April 2022, Grifols acquired a majority stake for EUR 1,091 million, leading Grifols to hold 96.
2% of ordinary shares. The company has made two notable deals to date, with the most recent occurring in April 2022. The founding history of the company is not detailed in available documents. Biotest AG specializes in developing, producing, and marketing innovative medical therapies in hematology, clinical immunology, and intensive care medicine.
Their core products include plasma-derived therapies and immunoglobulins like Haemoctin®, Yimmugo®, and Pentaglobin®. These products are designed to manage severe medical conditions, including hemophilia and immune deficiencies, and are marketed primarily in Europe and the United States, catering to healthcare providers in need of specialized treatments. In the most recent financial year 2024, Biotest AG reported revenue of EUR 740,892,063. 60 and an EBITDA of EUR 194,151,382.
10. The company generates revenue through sales to hospitals and clinics, focusing on its range of pharmaceutical products, particularly immunoglobulins and therapies for hemophilia, which are essential in medical settings. In April 2022, Biotest AG entered a transformative phase following Grifols' acquisition, aiming for strategic growth in new markets. With the support of the recent funding, Biotest plans to enhance its research and development efforts for upcoming therapies and expand its market presence, specifically targeting regions in Asia and Latin America by 2025.
The funding will facilitate the development of new products tailored to meet unmet medical needs within these regions.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.biotest.com
Verticals
Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Biotest AG - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Biotest AG | - | ||||||||
| Public to Private | Completed | Biotest AG | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.